Table 2.
Comorbidities and medication of the three study populations (a, b, and c).
| Parameter | Broad range of body mass index (n = 74) | Broad activity pattern (n = 43) | Broad range of disordered eating (n = 85) | ||||
|---|---|---|---|---|---|---|---|
| Anorexia nervosa (n = 15) | Normal weight (n = 15) | Obesity BMI 30–40 kg/m2 (n = 15) | Obesity BMI 40–50 kg/m2 (n = 14) | Obesity BMI > 50 kg/m2 (n = 15) | |||
| COMORBIDITIES | |||||||
| Type 2 diabetes mellitus | 0 (0.0%) | 0 (0.0%) | 4 (26.7%) | 3 (21.4%) | 6 (40.0%) | 0 (0.0%) | 19 (22.4%) |
| Impaired fasting glucose | n.t. | n.t. | 0 (0.0%) | 1 (7.1%) | 0 (0.0%) | n.t. | 4 (4.7%) |
| Insulin resistance with normal glucose control | n.t. | n.t. | 0 (0.0%) | 3 (21.4%) | 3 (20.0%) | n.t. | 22 (25.9%) |
| Arterial hypertension | 0 (0.0%) | 2 (13.3%) | 7 (46.7%) | 9 (64.3%) | 10 (66.7%) | 0 (0.0%) | 40 (47.1%) |
| Hypercholesterinemia | 1 (6.7%) | 1 (6.7%) | 5 (33.3%) | 5 (35.7%) | 9 (60.0%) | 8 (18.6%) | 39 (45.9%) |
| Hypertriglyceridemia | 0 (0.0%) | 0 (0.0%) | 2 (13.3%) | 3 (21.4%) | 4 (26.7%) | 0 (0.0%) | 16 (18.8%) |
| Hyperuricemia | 0 (0.0%) | 0 (0.0%) | 2 (13.3%) | 4 (28.6%) | 9 (60.0%) | 1 (2.3%) | 32 (37.6%) |
| Fatty liver disease | 0 (0.0%) | 0 (0.0%) | 9 (60.0%) | 9 (64.3%) | 3 (20.0%) | 0 (0.0%) | 48 (56.5%) |
| MEDICATION | |||||||
| Oral antidiabetics | 0 (0.0%) | 0 (0.0%) | 1 (6.7%) | 1 (7.1%) | 2 (13.3%) | 0 (0.0%) | 10 (11.8%) |
| Insulin | 0 (0.0%) | 0 (0.0%) | 1 (6.7%) | 1 (7.1%) | 0 (0.0%) | 0 (0.0%) | 3 (3.5%) |
| Statins | 0 (0.0%) | 0 (0.0%) | 1 (6.7%) | 0 (0.0%) | 4 (26.7%) | 0 (0.0%) | 11 (12.9%) |
| Psychopharmacologicals | 3 (20.0%) | 2 (13.3%) | 4 (26.7%) | 1 (7.1%) | 3 (20.0%) | 7 (16.3%) | 27 (31.8%) |
Values are given in total numbers (% in parentheses). AN, anorexia nervosa; BMI, body mass index; n.t., not tested.